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Abstract
Purpose Dry mouth is a highly prevalent and significant symptom in patients with advanced progressive diseases. It is a poorly
understood area of research, and currently, there is no standardised outcome measure or assessment tool for dry mouth.
Methods To assess responses to self-reported dry mouth questions, the impact of dry mouth, methods used to reduce symptoms
and relevance of the questionnaire. A cross-sectional multisite study of 135 patients with advanced progressive disease experienc-
ing dry mouth. Participants were located in the inpatient, day care, outpatient or community setting.
Results The majority (84.4%) of patients rated their dry mouth as moderate or severe using the verbal rating scale
(VRS). Seventy-five percent (74.7%) had a numeric rating scale (NRS) score of 6 or more for dry mouth severity.
Patients reported that dry mouth interfered most with talking and was the most important function to assess (median
score 6 out of 10) followed by eating (median 5) and taste (median 5). Taking sips of drink was the most common
and most effective self-management strategy. Over half of patients (54.6%) also reported impact on swallow and
sleep and associated dryness of lips, throat and nasal passages.
Conclusions This study highlights the severity of dry mouth in advanced disease. Important factors when assessing patients with
dry mouth should include the functional impact on day-to-day activities including talking, dysphagia and sleep. Simple consid-
erations for patients include provision of drinks and reviewing medications. This study could be used to develop a standardised
assessment tool for dry mouth to use in clinical practice.
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Introduction
Dry mouth is a highly prevalent and significant symptom for
patients with advanced progressive diseases. The estimated
prevalence of dry mouth in the general population is between
21 and 27% [1]. In a UK study of 197 terminally ill cancer
patients, it was the most prevalent symptom, occurring in 77%
[2]. Dry mouth was described as the ‘orphan topic in support-
ive care’ in 1997 [3], as, up until this time, the research in dry
mouth was largely in healthy patients, those with Sjogren’s
syndrome, or in those who had received radiotherapy to the
head and neck.
One of the first studies on the epidemiology, aetiology and
clinical features of dry mouth in advanced cancer patients was
published in 2001 [4]. In this study, 78% of 120 pa-
tients reported dry mouth; it was the fourth most com-
mon symptom reported on a Memorial symptom assess-
ment scale (MSAS) and the 3rd most distressing symp-
tom. The majority (75%) of the patients reported by
Davies [4] experienced dry mouth either ‘frequently’
or ‘almost constantly’, and 86% rated the severity as either
‘moderate’, ‘severe’ or ‘very severe’.
Saliva has a number of key functions, the most important of
which is to lubricate food prior to swallowing. Saliva consists
of more than 99% water, and along with secretions containing
mucin glycoproteins, it helps to coat, lubricate and protect the
hard and soft surfaces of the oral cavity [5–7]. It contains
amylase for digestion of starch and lingual lipase for fat di-
gestion [5]. Saliva has an antibacterial function, containing
lysozymes that break down bacterial cell walls [5, 7]. The
salivary flow is increased by mastication, and this allows for
bolus formation and swallowing. Saliva triggers thirst
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perception and enhances taste perception [5]. Dry mouth can
result in functional difficulties such as difficulty chewing, dif-
ficulty swallowing (dysphagia) and taste disturbance
(dysgeusia). Persistent dry mouth also predisposes to oral in-
fections, dental caries and oral candidiasis [5, 8]. Furthermore,
patients report dry mouth as a distressing symptom with a
significant impact on their quality of life [9].
Drug treatment is the most common cause of dry mouth in
the general population [10]. Patients with advanced diseases
are often prescribed a large number of medications, many of
which have recognised anticholinergic effects, such as opi-
oids, corticosteroids and benzodiazepines [11], and cannot
be discontinued due to refractory symptomatology.
‘Anticholinergic load’ has been recently studied in a retro-
spective review of patients with advanced diseases at the end
of life. In 199 patients, 60% received anticholinergic medica-
tion in the last 72 h of life [12].
There are few treatments licenced for use to help this con-
dition. A systematic literature review on the management of
dry mouth in advanced cancer patients identified only three
randomised controlled trials and three prospective studies
[13]. Overall, randomised controlled trials support the use of
pilocarpine, artificial saliva and chewing gum for the manage-
ment of xerostomia [14–16]. However, the evidence is of low
quality.
Dry mouth in patients with advanced progressive diseases
is a poorly understood area of research. Studies reporting on
the assessment of dry mouth and outcomes of interventions
have used varying scales and tools [14–18]. Some researchers
used additional symptoms other than dry mouth such as dys-
phagia, dysgeusia and dysarthria. Secondary outcomes have
included the use of additional questionnaires relating to over-
all opinion and preference to continue treatment [14, 15]. A
more recent study has used validated tools from non-palliative
care populations [18]. The Memorial symptom assessment
scale (MSAS) and the Edmonton symptom assessment scale
(ESAS) are validated symptom assessment tools commonly
used in the palliative care population, but they are not specific
for dry mouth. There is no consensus on the most valid ap-
proach that also incorporates the functional impact on the
patient. To our knowledge, there is no validated dry mouth
assessment tool for the palliative care patient.
Aim
The aims of this study were to assess, in a population of
palliative care patients with dry mouth, responses to different
measures of self-reported dry mouth questions; the impact of
dry mouth on day-to-day activities such as eating, talking and
taste; and methods used to reduce symptoms. A secondary
aim was to assess what parts of the questionnaire patients
found most relevant to their dry mouth.
Methods
Study design
This is an exploratory cross-sectional study designed to assess
the important factors in the clinical assessment of dry mouth
for the palliative care patients using questionnaires adminis-
tered face-to-face. The study received NHS Research Ethics
Committee approval on 12 October 2015 (IRAS Project ID
182067).
Setting
Recruitment took place over four sites. Three hospices
(palliative care inpatient units) and one large teaching
hospital all based within the north of England were
included. Recruitment took place between 1 December
2015 and 30 November 2016.
Participants
Eligible patients were at least 18 years of age with
advanced disease who had either been referred to palli-
ative care services or had been identified as being with-
in the last year of life were identified as having dry
mouth, either by clinical staff or self-reported during
clinical assessment, and who had the ability to consent
to the study. All patients were included irrespective of
the cause of their dry mouth. Participants were located
in the inpatient, day care, outpatient or community
setting.
Eligible patients were provided with information on
the study, and those who consented to take part were
included in the study. Written consent was obtained
from all participants.
Questionnaire
The questionnaire incorporated assessment tools used to as-
sess dry mouth in palliative care, identified through a literature
search, and clinical questions used in routine practice. Patients
included in the study were taken through the questionnaire by
the researcher face-to-face, and responses were recorded by
the researcher. Interviews took no longer than 15 min to
complete.
The questionnaire contained questions covering the
following:
Dry mouth severity
Patients were asked to respond to the question ‘Does
your mouth usually feel dry?’ using a dichotomous re-
sponse, responding ‘Yes’ or ‘No’. Patients were then
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asked ‘Tell me about your dry mouth’ using the following
2 scales:
& A numeric response using a numeric rating scale (NRS)
between 0 and 10, with 0 representing ‘No dryness’ and
10 representing ‘Worst imaginable dryness’.
& A descriptive response using a verbal rating scale (VRS)
including the categories ‘None’, ‘Mild’, ‘Moderate’ or
‘Severe’.
Interference
Patients were asked about the impact of dry mouth on talking,
eating and taste using a numeric rating scale (NRS) of 0–10,
with 0 representing ‘No interference’ and 10 representing
‘Significant interference’. The three questions were:
& Does your dry mouth interfere with talking?
& Does your dry mouth interfere with eating?
& Does your dry mouth interfere with taste?
Self-management
Patients were asked if they needed to use things to keep their
mouth moist and were prompted to report, using free text,
what these things were.
Other concerns
Patients were asked to respond ‘Yes’ or ‘No’ to the question:
‘Is there something not already mentioned that is of partic-
ular concern as a result of dry mouth? When patients
responded ‘Yes’, concerns were recorded as free text.
Question assessment
Patients were asked three additional questions to identify the
items in the questionnaire which they felt ‘best sums up their
dry mouth’, they ‘found easiest to complete’ and they ‘found
hardest to complete’.
Patient characteristics
Patient’s demographic characteristics of age, gender, diagno-
sis, the commonly used clinical assessment domains of illness
phase (Stable, Unstable, Deteriorating or Terminal) and per-
formance status (recorded using either the Karnofsky perfor-
mance status or the Barthel score) and drug history were ob-
tained from the clinical notes. The Barthel Index is an objec-
tive tool [19] using a sum score (0–100) across ten domains
which assesses an individual’s ability to perform activities of
daily living. It has been used in patients with advanced illness
and in terminally ill hospice patients, a rate of change in
Barthel score has been correlated with survival [20]. The
Karnofsky performance scale (KPS) and more recently the
Australian Karnofsky performance scale (AKPS) assesses
functional performance on an 11-point scale from 0 to 100%
and is important in resource utilisation in palliative care [21].
The total anticholinergic load of the patient’s medication was
recorded using an anticholinergic drug scale (ADS) [22].
Statistical analysis
Categorical patient characteristics and responses to the dry
mouth questionnaire were summarised using frequencies (n)
and percentages. Responses to numeric rating scales in the dry
mouth questionnaire were summarised using the median and
inter-quartile range (IQR), for skewed data, and the mean, and
standard deviation (SD) for non-skewed data.
The association between dry mouth severity NRS and per-
formance status was assessed using the Spearman’s rank cor-
relation coefficient. Differences in dry mouth severity NRS
between categorical variables were compared using the
Mann-Whitney U test, for two group comparisons, or the
Kruskal-Wallis H test, for more than two groups.
Data was analysed using SPSS statistical software (version
22-24). A two-tailed p value of less than 0.05 was used to
define statistical significance.
Results
Table 1 provides a summary of patient characteristics.
Patient demographics
One hundred thirty-five patients completed the questionnaire.
Over 60% (60.7%) were female. The age of patients ranged
from 32 to 92 years, with a mean age of 71 years (SD 11.2).
Seventy-seven percent (77%) had a diagnosis of malignancy;
lung cancer was the most common malignancy (18.5%)
followed by breast cancer (8.9%) and colorectal cancer
(7.4%). COPD was the most common non-malignant disease
and accounted for 12% of participant’s diagnoses.
Over half of patients (57.8%) had a Barthel Index score
recorded, with the remainder assessed using the Karnofsky
performance status; one patient had been assessed using both
measures. Only one patient was not taking medications that
had anticholinergic activity. The mean anticholinergic load
score on the ADS was 3.9 (SD 2.4). Typical medications in-
cluded opioids, corticosteroids, anti-emetics and benzodiaze-
pines. Though all patients were identified as having a dry
mouth, just over 15% (15.6%) of patients reported that their
dry mouth did not usually feel dry using the dichotomous
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scale. Almost half (48%) of those reported that the dry mouth
was a new or recent occurrence during their hospital
admission.
Dry mouth severity
Most patients reported that they usually had a dry mouth
(n = 112, 83.0%).
Patients reported on the current severity of their dry
mouth, using the VRS and NRS scales. The lowest
VRS rating for usual dry mouth was ‘Mild’, with
84.4% of patients rating their current dry mouth as ei-
ther moderate or severe. The lowest NRS rating was 2
out of 10, with a median current dry mouth severity of
7 (IQR = 3). Seventy-five percent (74.7%) had a NRS
score of 6 or more.
There was a significant positive relationship between the
distribution of responses to the NRS dry mouth severity score
and the responses to the VRS dry mouth severity score
(Kruskal-Wallis = 63.10, df = 2, p < 0.001), suggesting
consistency between dry mouth severity scoring using
the two scales. Median scores increased with each
VRS category increase (mild: median = 5, IQR = 2; mod-
erate: median = 7, IQR = 3; severe: median = 9, IQR = 2),
though there was overlap in NRS responses between
VRS responses (Fig. 1).
Interference with talking, eating or taste
Table 2 shows the distribution of responses to the questions
relating to howmuch dry mouth interferes with talking, eating
or taste. Most patients reported some (response 1 or more out
of 10) interference with talking (75.6%), eating (61.2%) or
taste (59.7%), with only 13.3% of patients (n = 18) reporting
no interference for all of these three measures. Patients report-
ed a median score of 6 out of 10 (IQR 7) for interference with
talking, and 5 out of 10 for interference with eating (IQR 7) or
taste (IQR 5).
The distribution of responses differed significantly for cur-
rent dry mouth responses using VRSwith the level of reported
interference increasingwith the severity of dry mouth reported
(talking: K-W = 39.13, p < 0.001; eating: K-W = 15.94,
p < 0.001; taste: K-W = 11.58, p = 0.003).
Table 1 Patient characteristics
Patient characteristics n Column %
Total 135 100.0
Gender
Male 53 39.3
Female 82 60.7
Age groups
Mean (SD) 71.2 (11.2)
Primary diagnosis
Breast 12 8.9
Lung 25 18.5
Colorectal 10 7.4
Other malignancy 57 42.2
Non-malignancy 31 23.0
Stage of illness
Stable 61 45.2
Unstable 44 32.6
Deteriorating 27 20.0
Terminal 2 1.5
Missing 1 0.7
Karnofsky performance status (10–100)
Count 56
Mean (SD) 54.8 (19.2)
Barthel Index (0–100)
Count 78
Mean (SD) 71.3 (21.7)
Total anticholinergic load
0 1
1–12 134
Mean (SD) 3.9 (2.4)
Does your mouth usually feel dry?
Yes 112 83.0
No 21 15.6
Missing 2 1.5
Severity of current dry mouth: verbal rating scale (VRS)
None 0 0.0
Mild 21 15.6
Moderate 67 49.6
Severe 47 34.8
Severity of current dry mouth: numerical rating scale (NRS, 0–10)
0 0 0.0
1 0 0.0
2 3 2.2
3 1 0.7
4 7 5.2
5 23 17.0
6 17 12.6
7 23 17.0
8 30 22.2
9 13 9.6
Table 1 (continued)
Patient characteristics n Column %
10 18 13.3
Median 7
IQR 3 (5 to 8)
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Current severity of dry mouth reported on the NRS had
significant positive relationships with interference with
talking, eating and taste (talking: rs = 0.491, p < 0.001; eating:
rs = 0.338, p < 0.001; taste: rs = 0.282, p = 0.001) (Table 3).
Self-management
Almost all patients (n = 131, 97.0%) reported that they needed
interventions to help keep their mouth moist. Table 4 shows
the types of items patients reported using to keep their mouth
moist. Of the patients who reported using items for moisture,
64.6% reported using more than one (Table 4). Multiple items
included a combination of non-pharmacological aids such as
drinks, sweets and mouthwashes and pharmacological aids
such as salivary substitute sprays and gels. Almost all
(93.4%) of the patients who reported using single options used
drinks alone. Other methods reported were toothpaste and
chewing gum.
Table 2 Patient responses to
interference with talking, eating
or taste, measured on a 0–10
scale, by severity of current dry
mouth, measured using the verbal
rating scale (VRS)
Interference
with:
VRS
response
(Response = 0)
no interference
(Response > 0)
some interference
Median IQR
n Row % n Row %
Talking
Mild 10 47.6 11 52.4 1 4 (0 to 4)
Moderate 19 28.4 48 71.6 5 7 (0 to 7)
Severe 4 8.5 43 91.5 8 2 (7 to 9)
Total 33 24.4 102 75.6 6 7 (1 to 8)
Eating
Mild 12 57.1 9 42.9 0 5 (0 to 5)
Moderate 29 43.3 38 56.7 4 7 (0 to 7)
Severe 11 23.9 35 76.1 7 7 (0.75 to 8)
Total 52 38.8 82 61.2 5 7 (0 to 7)
Taste
Mild 10 47.6 11 52.4 2 5 (0 to 5)
Moderate 32 47.8 35 52.2 3 7 (0 to 7)
Severe 12 26.1 34 73.9 6.5 8 (0 to 8)
Total 54 40.3 80 59.7 5 7 (0 to 7)
Fig. 1 Distribution of dry mouth
NRS responses by VRS
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Other concerns
Almost half of the patients (n = 65, 48.1%) responded ‘Yes’ to
the question ‘Is there something not already mentioned that is
of particular concern as a result of dry mouth’:
& 24.6% (n = 16) mentioned that their lips, throat or nasal
passages were also dry.
& 15% (n = 10) of patients mentioned that it woke them up at
night.
& 15% (n = 10) mentioned that their dry mouth affected their
swallow and resulted in a change in diet, a reduction in
intake of food and even drinks.
& 7.6% (n = 5) mentioned that they felt the cause may have
been due to medications. A further 7 patients mentioned that
medications were the reason for the new onset of drymouth.
Question assessment
Table 5 shows the question which patients thought best
summed up their dry mouth. Interference with talking was
the most popular question to sum up their dry mouth. The
three questions on interference combined were identified by
44.4% (n = 60) of patients as including a question which best
summed up their dry mouth, compared with 25.9% (n = 35) of
patients who chose one of the severity scales.
Discussion
Our study found that most patients with advanced disease that
have previously been identified as having a dry mouth rated
their dry mouth as moderate or severe using a VRS, or at least
a 6 out of 10 on a NRS, for dry mouth severity. The responses
patients provided for the VRS scale were consistent with the
NRS scale.
Table 3 Association between responses to the dry mouth numerical
rating scale (NRS) and interference with talking, eating and taste
Numerical rating scale (NRS) Talking Eating Taste
β coefficient 0.77 0.57 0.51
Standard error of β coefficient 0.13 0.15 0.16
Spearman’s rank correlation (rs) 0.49 0.34 0.28
p value < 0.001 < 0.001 0.001
Table 4 Items reported to help
keep the mouth moist Dry mouth response Drinks Sweets Other Multiple Total
n Row % n Row % n Row % n Row %
Total 43 33.1 1 0.8 2 1.5 84 64.6 130
Verbal rating scale (VRS)
Mild 8 38.1 0 0.0 1 4.8 12 57.1 21
Moderate 23 36.5 0 0.0 1 1.6 39 61.9 63
Severe 12 26.1 1 2.2 0 0.0 33 71.7 46
Numerical rating scale (NRS)
2 1 33.3 0 0.0 0 0.0 2 66.7 3
3 1 100.0 0 0.0 0 0.0 0 0.0 1
4 4 57.1 0 0.0 0 0.0 3 42.9 7
5 6 30.0 0 0.0 1 5.0 13 65.0 20
6 9 52.9 0 0.0 1 5.9 7 41.2 17
7 4 19.0 0 0.0 0 0.0 17 81.0 21
8 13 43.3 0 0.0 0 0.0 17 56.7 30
9 3 23.1 1 7.7 0 0.0 9 69.2 13
10 2 11.1 0 0.0 0 0.0 16 88.9 18
Table 5 Responses to question: Which question/measure best sums up
your dry mouth?
Response: n Column %
Dry mouth severity: dichotomous 3 2.2
Dry mouth severity: NRS 23 17.0
Dry mouth severity: VRS 9 6.7
Interference: talking 32 23.7
Interference: eating 11 8.1
Interference: taste 12 8.9
Interference: all 3 questions 5 3.7
Other concerns 2 1.5
Unsure/no preference 32 23.7
Missing 6 4.4
Total 135 100.0
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Over 85% of patients reported that dry mouth interfered, at
least to some extent, with talking, eating or taste. The extent to
which dry mouth interfered was significantly related to the
reported severity of dry mouth. Interference with talking due
to dry mouth was the most common problem, with three quar-
ters of patients reporting at least some interference with
talking. Nearly one quarter of patients also identified this
question as the measure which best summed up their dry
mouth. Facilitating time for patients to have a drink during a
consultation can ease this burden [23].
Correlation of dry mouth and impact on talking has been
noted in previous studies [4, 14]. The study by Sweeney [14]
of 35 hospice patients used visual analogue scale (VAS) scores
at baseline and following administration of saliva spray or
placebo. They found, at baseline, 82.8% reported none or mild
dry mouth during the day. In contrast, our study found only
15.6% rated their dry mouth as none to mild. Sweeney [14]
also found 80% had either no difficulty or mild difficulty with
talking compared with 15.5% in our study. Furthermore,
88.2% had either no or mild impact on eating compared with
our study which found only 15.5% reported none or mild
interference with eating. These differences may reflect the
small sample used in the Sweeney study but may also reflect
the different methods used to assess dry mouth, with Sweeney
using a 7-point Likert scale (response 0–6) and reducing this
to three categories: no problem (0), mild problem (1–3) and
severe problem (4–6).
Nearly all patients reported needing to use things to keep
their mouth moist, with most patients using a range of both
pharmacological and non-pharmacological items. Drinks were
the commonest single method used to alleviate dry mouth and
evidence from free text suggested water was as effective.
Salivary substitutes replace oral moisture only and need to
be taken very regularly including during meals. Salivary stim-
ulants or sialogogues such as pilocarpine, bethanechol and
cevimeline improve salivary flow by agonist action at musca-
rinic cholinergic receptors. Pilocarpine functions primarily as
a muscarinic-cholinergic agonist with mild beta-adrenergic
activity and is licenced for dry mouth following radiotherapy
for head and neck cancer and in Sjogren’s syndrome [24].
A systematic review considered the effectiveness of non-
systemic topical interventions in dry mouth from a range of
aetiologies [25]. Evidence was found to be limited. A system-
atic review to determine the effectiveness of pharmacological
and non-pharmacological interventions in treating dry mouth
in advanced cancer patients (excluding dry mouth caused spe-
cifically by radiotherapy, surgery, graft versus host disease and
autoimmune diseases) identified only three randomised con-
trolled trials, the majority of which were not statistically sig-
nificant [13]. The review highlighted the paucity of the evi-
dence base. A recent feasibility study of pilocarpine in ad-
vanced cancer patients found that the treatment was unaccept-
able to most patients due to its side effect profile [18].
Basic mouth care can be effective in managing dry mouth.
The spontaneous improvement in dry mouth in the palliative
care studies could be related to the greater emphasis on mouth
care [13]. A study involving elderly patients in a long-term
care facility found that tooth brushing and mouthwash de-
creased dry mouth and oral tongue plaques [26]. Other simple
measures such as taking sips of water found in our study can
be effective for providing symptomatic relief.
Nearly half of all patients reported that they had other con-
cerns that had not been identified in the questionnaire. The
most common concern was around associated dryness of lips,
throat and nasal passages. Simply addressing the dry mouth is
often not enough. Maintaining moist lips and nasal passages
appears to be important for patients and can be helped by the
administration of simple water-based gels and ensuring humid-
ification [23, 27]. Another common concern was around dys-
phagia and the perception of dysphagia. This can have effects
on patient’s diet as well as impact on the fluid intake, further
contributing to the symptom of dry mouth [28]. Many patients
reported a disturbance in sleep. Simple attention to ensuring a
drink is by the bedside of patients can help minimise distur-
bance and may result in better quality sleep. Almost half of the
patients who reported to not ‘usually feel dry’ reported that the
dry mouth was a new or recent occurrence in hospital. The
association of dry mouth with the commencement of medica-
tions was also highlighted. Therefore, reviewing their effec-
tiveness and examining the potential for dose reduction or
discontinuation may lead to improvements in dry mouth with-
out compromising control of other symptoms.
In a study in an advanced cancer population [16], the mean
number of medications was 2 (range 0–4). We found that the
mean number of medications was 3.9 (SD 2.4). This could
reflect more medication burden in a palliative care population.
Typical medications in our study included opioids, corticoste-
roids, anti-emetics and benzodiazepines. These were similar to
Agar [11].
Of patients who had a preference as to the question or
measure which was most relevant to their dry mouth, ‘numeric
rating scale’ and ‘interference with talking’ were the most
commonly reported. A useful assessment tool for dry mouth
could incorporate both of these measures. As the responses
patients provided for the VRS scale were consistent with the
NRS scale, NRS on its own could be used as a measure for
severity. In studies measuring pain, NRS has been found to
have higher compliance rates, better responsiveness and ease
of use compared with both VRS and VAS [29]. We have not
found any studies that have asked patients additional informa-
tion unspecific to their dry mouth or of self-management strat-
egies. Additionally, our questionnaire assessed what patients
thought about the questionnaire itself. In this study, the free
text proved to be a valuable addition to assess patient’s con-
cerns and would further enhance an assessment tool for dry
mouth in the palliative care population.
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Sialometry was not used in our study. From our review of
objective measurements used in the measurement of dry
mouth, salivary collection was not routinely undertaken in
the palliative care population [15–17]. Of those used, proce-
dures were limited and the results were not statistically signif-
icant [14]. From a search of the use of sialometry in other
populations, it was discovered that some patients who com-
plain of dry mouth do not demonstrate reduced flow rates and
conversely, some individuals demonstrate an objective de-
crease in the flow of saliva but do not complain of oral dryness
[30, 31]. Furthermore, Davies [4] found that the relationship
between dry mouth and resting whole salivary flow rate
(UWSFR) was a relatively sensitive (sensitivity 85%) but a
non-specific (specificity 30%) method of detecting
xerostomia. Similarly, the relationship between dry mouth
and stimulated whole salivary flow rate (SWSFR) is a rela-
tively specific (specificity 78%) but insensitive (sensitivity
47%) method for detecting xerostomia. Based on these find-
ings, the authors suggested that there is no indication for the
routine measurement of salivary flow rates in the clinical as-
sessment of patients complaining of dry mouth. Furthermore,
we did not want to include a burdensome procedure for the
palliative care patients in the study.
Our study was reliant on routinely collected patient data.
Different measures were collected which limited the ability to
compare data. We used questions taken directly from different
assessment tools and amalgamated them into one question-
naire. Though we recognised at the outset the inconsistency
in the wording within the questionnaire, the aim of the study
was to assess responses to different dry mouth questions for a
palliative care population.
To minimise bias involved in an observational study using
face-to-face questioning, the researchers were not part of the
usual clinical team.
This was a cross-sectional study of 135 palliative care pa-
tients and as far as we can tell the only study of this kind. It
highlights the severity of dry mouth for patients in the inpa-
tient, day care, outpatient or community setting. To date, there
is no consensus on the most valid approach to assessing dry
mouth. This study describes the important factors required in a
clinical assessment of dry mouth and reminds clinicians to
consider the functional impact as well as the severity of the
symptom on the patient.
Conclusions
Given the prevalence and impact of dry mouth in advanced
disease, and the paucity of the existing evidence base, more
research is needed if improvements in quality of life are to be
realised for these patients. Improving research methodology is
most likely to lead to important improvements in clinical care
for patients with dry mouth in the context of advanced disease.
This study highlights that dry mouth in patients with advanced
disease can have a significant negative impact on the day-to-
day ability to talk, eat and taste and can interfere with nasal
passages, lips, throat, swallowing and sleep. This data can be
used to describe what dry mouth means for a palliative care
patient and can be used as an outcome measure in managing
and assessing dry mouth. Outcomes from this study could
help inform future development of an assessment tool for
dry mouth in palliative care patients to be used in clinical
practice.
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